The company has sold its 100% stake held in Broadway Hospitality Services

Broadway has ceased to be a wholly owned subsidiary of the company with effect from August 31, 2026

The latest partnership further reinforces the company’s commitment to expanding its diabetes portfolio and bringing a broader range of treatment options to patients in India

The company has incorporated WOS under the name and style of ‘Mankind Pharma (Netherlands) B.V.’

The company has incorporated WOS under the name and style of ‘Mankind Pharma (Netherlands) B.V.’

Consolidated total income of the company increased by 11.65% to Rs 4,075.59 crore in Q1FY27.

The Board of Directors of the company at its meeting held on July 11, 2026, has inter-alia, considered and approved the same

This acquisition will enable the company to achieve better operational efficiencies through streamlined processes

This acquisition will enable the company to achieve better operational efficiencies through streamlined processes

The Board of Directors of the Company at its meeting held May 19, 2026, has approved the same

The Board of Directors of the Company at its meeting held May 19, 2026, has approved the same

Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions

Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions

Total consolidated income of the company increased by 11.12% at Rs 3,639.95 crore for Q3FY26

The consolidated total income of the company increased by 19.51% at Rs 3,789.03 crore for Q2FY26

The company will acquire the business at a consideration of Rs 797 crore

The molecule is being developed for the treatment of multiple autoimmune disorders, including rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia

Mankind Pharma LLC shall carry out the business of distribution of pharmaceutical products of Bharat Serums and Vaccines

Mankind Pharma LLC shall carry out the business of distribution of pharmaceutical products of Bharat Serums and Vaccines

The total consolidated income of the company increased by 23.02% at Rs 3650.23 crore for Q1FY26

The total consolidated income of the company increased by 23.02% at Rs 3650.23 crore for Q1FY26

The company has received ESG score of 38.98 from ISS ESG

The company has not verified any data on which this rating has been issued

The total consolidated income of the company increased by 32.47% at Rs 3,330.70 crore for Q4FY25

The Board of Directors of the Company at its meeting held on May 21, 2025, has approved the same

The Board of Directors of the Company at its meeting held on April 14, 2025, has inter-alia, considered and approved the same

This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region

BSV’s established domestic product portfolio offers huge scalability potential through strong registration velocity through niche filings across international markets

The agreement is for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate brand Symbicort in India

The agreement is for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate brand Symbicort in India

The shares were disposed of at an average price of Rs 2,107.35 apiece, taking the combined deal value to Rs 1,367.57 crore

Post this investment the aggregate shareholding of the Company in Actimed will be around 10.19%

Post this investment the aggregate shareholding of the Company in Actimed will be around 10.19%

The scrip is currently trading at Rs 1388.30, up by 308.30 points or 28.55% from its issue price

The issue will open for subscription on April 25, 2023 and will close on April 27, 2023